MDNAF (Medicenna Therapeutics) Other Stockholders Equity: $-0.00 Mil (As of Mar. 2026)


MDNAF Medicenna Therapeutics Corp MDNAF
30 GF Score
Price $0.27
! 1 Warning Sign
View Full Analysis

What is Medicenna Therapeutics Other Stockholders Equity?

Medicenna Therapeutics MDNAF -7.12% 30 Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus rates MDNAF with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Medicenna Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $-0.00 Mil.

Medicenna Therapeutics's quarterly Other Stockholders Equity increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($-0.00 Mil) and increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil).

Medicenna Therapeutics's annual Other Stockholders Equity increased from Mar. 2024 ($0.00 Mil) to Mar. 2025 ($6.85 Mil) but then declined from Mar. 2025 ($6.85 Mil) to Mar. 2026 ($-0.00 Mil).

Medicenna Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Medicenna Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics Other Stockholders Equity Chart

Medicenna Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 0.00 6.85 -0.00

Medicenna Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.85 0.00 -0.00 -0.00 -0.00
MDNAF
30GF Score
Medicenna Therapeutics Corp MDNAF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicenna Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
Medicenna Therapeutics (MDNAF) has a Other Stockholders Equity of $-0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Medicenna Therapeutics and its competitors.
Is Medicenna Therapeutics' Other Stockholders Equity too high?
Medicenna Therapeutics' current Other Stockholders Equity is $-0.00 Mil. Overall, Medicenna Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' Other Stockholders Equity compare to VRTX and REGN?
Medicenna Therapeutics' Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Medicenna Therapeutics and its competitors. Medicenna Therapeutics's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (MDNAF) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. Medicenna Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Medicenna Therapeutics (MDNAF), the current Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicenna Therapeutics Business Description

Other Exchanges MDNA:Canada
Address 2 Bloor Street West, Suite 903, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
30GF Score

Get the complete analysis for MDNAF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.27
Price